• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.62% Nasdaq Down1.12%

    Acasti Pharma Inc. (ACST)

    0.32 Up 0.00(0.98%) 12:33PM EDT - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Acasti Pharma Inc.
    545 Promenade du Centropolis
    Suite 100
    Laval, QC H7T 0A3
    Canada - Map
    Phone: 450-686-4555
    Fax: 450-686-2505
    Website: http://www.acastipharma.com

    Index Membership:N/A
    Full Time Employees:7

    Business Summary 

    Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment and prevention of various cardiometabolic disorders primarily abnormalities in blood lipids. The company offers ONEMIA, a medical food for the dietary management of omega-3 phospholipids deficiency, and related abnormal lipid profiles and cardiometabolic disorders. It also develops CaPre, a prescription drug candidate for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. Acasti Pharma Inc. distributes ONEMIA through physicians, distributors, and pharmacies in the United States and internationally. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Acasti Pharma Inc.

    Key Executives 
    Mr. Pierre Lemieux Ph.D., M.D.,
    Chief Operating Officer
    Mr. John Ripplinger ,
    Director of Investor Relations
    Mr. Jean-Daniel Bélanger ,
    Director of Corp. Affairs and Corp. Sec.
    Dr. Farhad Amiri Ph.D.,
    Director of Preclinical Studies
    Mr. Laurent Harvey B. Pharm., M. Sc. ,
    VP of Clinical and Non-Clinical Affairs
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders